Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial.

MLA

Ikeda, Masafumi, et al. “Transarterial Chemoembolization with Miriplatin vs. Epirubicin for Unresectable Hepatocellular Carcinoma: A Phase III Randomized Trial.” Journal of Gastroenterology, vol. 53, no. 2, Feb. 2018, pp. 281–90. EBSCOhost, https://doi.org/10.1007/s00535-017-1374-6.

APA

Ikeda, M., Kudo, M., Aikata, H., Nagamatsu, H., Ishii, H., Yokosuka, O., Torimura, T., Morimoto, M., Ikeda, K., Kumada, H., Sato, T., Kawai, I., Yamashita, T., Horio, H., & Okusaka, T. (2018). Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial. Journal of Gastroenterology, 53(2), 281–290. https://doi.org/10.1007/s00535-017-1374-6

Chicago

Ikeda, Masafumi, Masatoshi Kudo, Hiroshi Aikata, Hiroaki Nagamatsu, Hiroshi Ishii, Osamu Yokosuka, Takuji Torimura, et al. 2018. “Transarterial Chemoembolization with Miriplatin vs. Epirubicin for Unresectable Hepatocellular Carcinoma: A Phase III Randomized Trial.” Journal of Gastroenterology 53 (2): 281–90. doi:10.1007/s00535-017-1374-6.